Upstream Bio presented Phase 2 VIBRANT trial results showing verekitug significantly improved asthma symptom control and reduced nasal polyp burden in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid asthma. The drug also lowered key inflammatory biomarkers and reduced the need for systemic steroids or surgery. These findings support the potential of verekitug as a new treatment option with quarterly dosing, with Phase 3 trials planned to start in early 2027.
Bouygues Telecom, Free-iliad Group, and Orange have signed a Memorandum of Understanding to acquire SFR from Altice France for a total enterprise value of €20.35 billion. The deal aims to create long-term value by strengthening France's digital infra...
Bouygues Telecom, alongside Free-iliad Group and Orange, signed a Memorandum of Understanding to acquire most of Altice France's SFR assets, excluding some subsidiaries and overseas operations. This strategic move aims to enhance investment in French...
Bouygues Telecom, Free-iliad Group, and Orange have signed a Memorandum of Understanding with Altice France to acquire SFR for a total enterprise value of €20.35 billion. This major telecom deal aims to strengthen France's digital infrastructure by c...
Bouygues Telecom, Free-Groupe iliad, and Orange have signed a preliminary agreement to jointly acquire SFR from Altice France for €20.35 billion. This major deal aims to create long-term value by supporting infrastructure development and maintaining ...
Ethena’s synthetic dollar token USDe has been listed on Mercado Bitcoin, Brazil’s largest crypto exchange, to meet growing demand for USD-pegged stablecoins in Latin America. USDe, launched in 2023, uses a unique delta-hedging strategy involving cryp...
